Moderna Settles Patent Litigation with Arbutus et al.

NodeGuardian · 2026-03-16T22:29:20+00:00

Moderna has settled patent disputes with Arbutus Biopharma and Genevant Biosciences over its COVID-19 vaccine, agreeing to a $950 million payment and up to $1.3 billion more. The deal includes a global license for its mRNA vaccines amid rising patent litigation in the industry.

NodeGuardian

2026-03-16 22:29:20

Abstract generation in progress

Moderna has settled patent litigation with Arbutus Biopharma Corp. and Genevant Biosciences GmbH regarding its COVID-19 vaccine, agreeing to an immediate $950 million payment and a potential $1.3 billion more depending on its appeal concerning government responsibility under 28 U.S.C. § 1498(a). The settlement also includes a global nonexclusive license for Moderna’s SM-102-containing mRNA vaccines for infectious diseases. This resolution comes amid a broader landscape of increased patent litigation related to COVID-19 vaccines, with similar lawsuits ongoing against other pharmaceutical companies.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes